Madhu Kumar
Stock Analyst at Goldman Sachs
(2.84)
# 1,611
Out of 5,241 analysts
133
Total ratings
55.1%
Success rate
19.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Madhu Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $162 → $185 | $228.77 | -19.13% | 8 | Aug 29, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $6.69 | -10.31% | 8 | Jan 26, 2024 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $7.04 | +141.48% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $2.16 | +85.19% | 4 | Sep 25, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $306.29 | -49.39% | 13 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $75.85 | -30.13% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $14.37 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $76.67 | -4.79% | 10 | May 3, 2023 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $39 → $34 | $20.23 | +68.07% | 6 | Mar 1, 2023 | |
| IOVA Iovance Biotherapeutics | Downgrades: Neutral | $20 → $6 | $3.45 | +73.91% | 8 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $14 | $7.47 | +87.42% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $33.09 | -84.89% | 3 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $8 | $2.62 | +205.34% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $111 → $89 | $9.08 | +880.18% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $580 → $120 | $5.22 | +2,198.85% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $85 | $13.67 | +521.80% | 7 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $23 → $39 | $3.97 | +882.37% | 3 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $58 → $57 | $27.05 | +110.72% | 3 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.24 | - | 15 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $0.93 | +96,663.79% | 1 | Apr 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $20 | $8.79 | +127.53% | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5,600 → $4,000 | $3.49 | +114,513.18% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $49.35 | -29.08% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $40 | $12.35 | +223.89% | 2 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $504 | $28.65 | +1,659.16% | 3 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $230 | $286.98 | -19.86% | 2 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $1,125 | $19.98 | +5,530.63% | 2 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $2.47 | +1,519.43% | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $39.50 | -45.57% | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $48.41 | -51.46% | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Aug 29, 2025
Maintains: Buy
Price Target: $162 → $185
Current: $228.77
Upside: -19.13%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $6.69
Upside: -10.31%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $7.04
Upside: +141.48%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $2.16
Upside: +85.19%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $306.29
Upside: -49.39%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $75.85
Upside: -30.13%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $14.37
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $76.67
Upside: -4.79%
Syndax Pharmaceuticals
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $20.23
Upside: +68.07%
Iovance Biotherapeutics
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $3.45
Upside: +73.91%
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $7.47
Upside: +87.42%
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $33.09
Upside: -84.89%
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $2.62
Upside: +205.34%
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $9.08
Upside: +880.18%
Jan 19, 2022
Downgrades: Neutral
Price Target: $580 → $120
Current: $5.22
Upside: +2,198.85%
Jun 23, 2021
Maintains: Neutral
Price Target: $60 → $85
Current: $13.67
Upside: +521.80%
Mar 16, 2021
Upgrades: Outperform
Price Target: $23 → $39
Current: $3.97
Upside: +882.37%
Jul 31, 2020
Upgrades: Outperform
Price Target: $58 → $57
Current: $27.05
Upside: +110.72%
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $4.24
Upside: -
Apr 21, 2020
Initiates: Outperform
Price Target: $900
Current: $0.93
Upside: +96,663.79%
Mar 27, 2020
Maintains: Underperform
Price Target: $17 → $20
Current: $8.79
Upside: +127.53%
Mar 13, 2020
Maintains: Buy
Price Target: $5,600 → $4,000
Current: $3.49
Upside: +114,513.18%
Mar 12, 2020
Initiates: Outperform
Price Target: $35
Current: $49.35
Upside: -29.08%
Sep 24, 2019
Maintains: Buy
Price Target: $58 → $40
Current: $12.35
Upside: +223.89%
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $28.65
Upside: +1,659.16%
Aug 13, 2018
Maintains: Buy
Price Target: $210 → $230
Current: $286.98
Upside: -19.86%
Feb 9, 2018
Maintains: Buy
Price Target: $150 → $1,125
Current: $19.98
Upside: +5,530.63%
Feb 8, 2018
Initiates: Buy
Price Target: $40
Current: $2.47
Upside: +1,519.43%
Dec 1, 2017
Reinstates: Buy
Price Target: $22
Current: $39.50
Upside: -45.57%
Mar 28, 2017
Initiates: Buy
Price Target: $24
Current: $48.41
Upside: -51.46%